MediWound Ltd.
NASDAQ:MDWDBiotechnology
-$0.09 today
- Market cap
- $175.71M
- Beta
- 0.15
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$2.03
Volume 0.17M
Average 0.09M
MDWD Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
MediWound Ltd.NASDAQ: MDWD
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow grows, but more slowly than its trailing trend
Q1 FY2026 financing cash flow of $421K (cash outflow) rose 16.3% year over year, behind the +54.5% change in trailing-twelve-month financing cash flow. Sequentially, it fell 73.3% from the prior quarter. Over 3 fiscal years it compounded at -6.1% a year.
Context
- Financing cash flow amounted to 174.7% of revenue in FY2025, up 78.8 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +16.3% toward the trailing-twelve-month pace of +54.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 29.62M USD
- Year-over-year change
- +52.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 29.62M | +52.7% |
| FY2024 | 2024-12-31 | 19.39M | -15.4% |
| FY2023 | 2023-12-31 | 22.92M | -35.9% |
| FY2022 | 2022-12-31 | 35.76M | +3506.1% |
| FY2021 | 2021-12-31 | (1.05M) | — |
Financing Cash Flow vs competitors
How MDWD compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +54.5% is the 6th highest of 9, against a peer median of +88.8%.
- Financing cash flow amounts to 210.5% of revenue for MDWD, versus a peer median of 633.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | €232M EUR | +59.4% | +84.0% | 5175.1% | |
| LTM Mar 2026 | $215.52M USD | +89700.8% | +652.5% | 385.8% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $122.33M USD | +380.3% | +92.7% | — |
| LTM Sep 2026 | $117.69M USD | +118.3% | +53.0% | — | |
| LTM Mar 2026 | $94.16M USD | +226.3% | -5.1% | 287.7% | |
| LTM Mar 2026 | $82.13M USD | -42.0% | — | — | |
| LTM Mar 2026 | $30.48M USD | +54.5% | -6.1% | 210.5% | |
| LTM Mar 2026 | $16.91M USD | — | — | — | |
| LTM Mar 2026 | $15.64M USD | -86.7% | — | 881.2% | |
| LTM Mar 2026 | $378K USD | -99.8% | +634.8% | — | |
| Peer median (excluding MDWD) | — | +88.8% | +88.3% | 633.5% | |
Competitors are the stored peer set for MDWD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.55M) | (19.6M) | (6.72M) | (30.22M) | (23.88M) |
| Depreciation & Amortization | 1.24M | 1.27M | 1.3M | 1.48M | 1.71M |
| Deferred Income Tax | (124K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.67M | 1.95M | 1.94M | 3.14M | 3.11M |
| Change in Working Capital | 162K | (7.24M) | 2.34M | 1.27M | 4.77M |
| Accounts Receivables | 929K | (7.58M) | 4.76M | (1.02M) | 4.88M |
| Inventory | 257K | (721K) | (906K) | 187K | (1.36M) |
| Accounts Payables | 1.72M | 414K | (594K) | 406K | 2.35M |
| Other Working Capital | (2.75M) | 645K | (928K) | 1.7M | (1.1M) |
| Other Non-Cash Items | 1.69M | 11.74M | (9.33M) | 10.71M | (236K) |
| Operating Cash Flow | (8.92M) | (11.89M) | (10.47M) | (13.62M) | (14.53M) |
| Capital Expenditures | (489K) | (555K) | (6.46M) | (6.27M) | (5.51M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (14.04M) |
| Sales of Investments | 4M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 35K | 74K | (27.86M) | (2.12M) | 0 |
| Investing Cash Flow | 3.55M | (481K) | (34.32M) | (8.4M) | (19.54M) |
| Debt Repayment | 0 | 0 | 0 | (928K) | 0 |
| Common Stock Issued | 3K | 38.38M | 24.91M | 22.17M | 31.05M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.05M) | (2.62M) | (1.99M) | (1.84M) | (1.43M) |
| Financing Cash Flow | (1.05M) | 35.76M | 22.92M | 19.39M | 29.62M |
| Effect of Forex Changes | 88K | (549K) | (160K) | (84K) | 95K |
| Net Change in Cash | (6.33M) | 22.85M | (22.03M) | (2.71M) | (4.36M) |
| Free Cash Flow | (9.41M) | (12.44M) | (16.93M) | (19.9M) | (20.04M) |
MediWound Ltd.
NASDAQ:MDWD
Intrinsic Alpha fair value
Locked
Current Price
$13.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.